- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00030420
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and docetaxel in treating patients who have advanced non-small cell lung cancer that has been previously treated with platinum-based chemotherapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
OBJECTIVES:
- Determine the efficacy and feasibility of celecoxib combined with docetaxel in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
- Determine the response rate of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral celecoxib twice daily (beginning on day -7 of the first course) and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses after CR. Patients who achieve stable disease (SD) or a partial response (PR) receive a minimum of 2 additional courses after SD or PR. At the discretion of the treating physician, patients then receive maintenance therapy comprising celecoxib only.
Patients who discontinue therapy for disease progression or unacceptable toxicity are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 21-39 patients will be accrued for this study within 13-28 months.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Diagnosis of stage IIIA, IIIB, or IV non-small cell lung cancer
- Disease progression during or after 1 or more platinum-based chemotherapy regimens
- Measurable or evaluable disease
No symptomatic or untreated brain or leptomeningeal metastases
- Previously treated patients must be neurologically stable for 4 weeks after completion of appropriate therapy
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- SWOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin no greater than upper limit of normal (ULN)
- AST/ALT no greater than ULN (or no greater than 2.5 times ULN if alkaline phosphatase no greater than ULN)
- Alkaline phosphatase no greater than ULN (or no greater than 5 times ULN if AST/ALT no greater than ULN)
- No history of chronic hepatitis of any duration
Renal:
- Creatinine no greater than ULN
Cardiovascular:
- No uncontrolled congestive heart failure
- No uncontrolled angina
- No myocardial infarction and/or stroke within the past 6 months
- No active thromboembolic event within the past 4 weeks
Gastrointestinal:
- No gastrointestinal bleeding within the past 6 months
- No history of peptic ulcer disease
Other:
- No prior hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
- No prior allergy to any non-steroidal anti-inflammatory drug
- No other prior or concurrent malignancy within the past 3 years except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
- No grade 2 or greater peripheral neuropathy
- No active infection
- No other serious concurrent medical illness
- No history of dementia, active psychiatric disorder, or other condition that would interfere with ability to take oral medication or preclude compliance with study
- HIV negative
- Must weigh at least 50 kg (110 pounds)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- Prior paclitaxel allowed
- No prior docetaxel
Endocrine therapy:
- At least 3 days since prior steroids
Radiotherapy:
- At least 4 weeks since prior radiotherapy
- No prior radiotherapy to target lesion
Surgery:
- At least 4 weeks since prior major surgery
Other:
- Prior intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs), including rofecoxib or celecoxib, allowed
- At least 1 week since prior fluconazole
- No recent prior NSAIDs, including rofecoxib or celecoxib, for a duration of more than 30 consecutive days
- No concurrent fluconazole or lithium
- No other concurrent NSAIDs except aspirin administered at a dose of no more than 325 mg/day for cardiovascular conditions
- No other concurrent cyclo-oxygenase-2 inhibitors
- No other concurrent investigational agents
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Celecoxib & Docetaxel
Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment. Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days |
400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
Autres noms:
On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Efficacy of combining Celecoxib with Docetaxel
Délai: Weeks 1 , 2 and 3
|
Blood levels of VEGF & PGE2
|
Weeks 1 , 2 and 3
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Response rate of Celecoxib and Docetaxel
Délai: Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation.
|
CT Chest/Abdomen
|
Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation.
|
Toxicity of Celecoxib and Docetaxel
Délai: Every week
|
Routine bloodwork
|
Every week
|
Expression of cyclooxygenase-2 (COX-2) in tumors
Délai: Pre-study
|
Tissue sample from initial diagnosis, parrafin embedded tissue block
|
Pre-study
|
Changes in plasma levels of prostaglandin E2 (PGE2) & vascular endthelial growth factor (VEGF)
Délai: Pre-study; Weeks 1 , 2 and 3
|
Collecting blood plasma
|
Pre-study; Weeks 1 , 2 and 3
|
Vascular changes induced in the tumor by celecoxib
Délai: Weeks 1, 3 & 6
|
Using DCE-MRI and PET scans to evaluate.
|
Weeks 1, 3 & 6
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Tumeurs
- Maladies pulmonaires
- Tumeurs par site
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs pulmonaires
- Carcinome pulmonaire non à petites cellules
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Inhibiteurs de la cyclooxygénase
- Agents antinéoplasiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Inhibiteurs de la cyclooxygénase 2
- Docétaxel
- Célécoxib
Autres numéros d'identification d'étude
- CDR0000069164
- P30CA022453 (Subvention/contrat des NIH des États-Unis)
- WSU-C-2304 (Autre identifiant: Barbara Ann Karmanos Cancer Institute)
- NCI-V01-1688
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Celecoxib
-
University of British ColumbiaObsessive Compulsive Foundation; BC Children's Hospital Research InstituteRecrutementTrouble obsessionnel compulsif | Trouble psychiatrique pédiatriqueCanada
-
HaEmek Medical Center, IsraelClalit Health ServicesRésiliéCancer colorectal métastatiqueIsraël